NEW YORK (GenomeWeb) – Proteomics firm Caprion Biosciences said today that it has been acquired by London-based healthcare investment firm GHO Capital.

GHO purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012. Caprion said that it will continue to operate out of its current Montreal headquarters under the leadership of its existing management team.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.